The oncogenic potential of a prostate cancer‐derived androgen receptor mutant

The role of androgen receptor (AR) mutations in the initiation of prostate cancer (CaP) remains unclear. The purpose of this study was to assess the influence of an AR mutation on prostate tumorigenesis and to determine the resulting molecular alterations.

[1]  J. Isaacs,et al.  Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. , 2006, Cancer research.

[2]  A. D. De Marzo,et al.  Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. , 2005, Cancer research.

[3]  R. Harte,et al.  Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors , 2005, BMC Genomics.

[4]  Michael Ittmann,et al.  Mutation of the androgen receptor causes oncogenic transformation of the prostate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Golub,et al.  Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells , 2004, Cancer Research.

[6]  W. Catalona,et al.  Analysis of Candidate Genes for Prostate Cancer , 2004, Human Heredity.

[7]  J. Gregg,et al.  Molecular alterations associated with LNCaP cell progression to androgen independence , 2004, The Prostate.

[8]  C. Nicholls,et al.  UV-dependent Alternative Splicing Uncouples p53 Activity and PIG3 Gene Function through Rapid Proteolytic Degradation* , 2004, Journal of Biological Chemistry.

[9]  P. Webb,et al.  A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor , 2004, Nuclear receptor.

[10]  R. Montironi,et al.  Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors , 2004, Virchows Archiv.

[11]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[12]  Kazuto Ito,et al.  Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia. , 2003, Anticancer research.

[13]  Hiroshi Sato,et al.  Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins. , 2003, Cancer research.

[14]  S. Sugano,et al.  Large-scale identification and characterization of human genes that activate NF-κB and MAPK signaling pathways , 2003, Oncogene.

[15]  T. Mak,et al.  Cutting Edge: Role of IL-27/WSX-1 Signaling for Induction of T-Bet Through Activation of STAT1 During Initial Th1 Commitment1 , 2003, The Journal of Immunology.

[16]  P. Carroll,et al.  Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. , 2003, Biochemical and biophysical research communications.

[17]  S. Hayward,et al.  Role of stroma in carcinogenesis of the prostate. , 2002, Differentiation; research in biological diversity.

[18]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Liang Xia,et al.  Functional analysis of 44 mutant androgen receptors from human prostate cancer. , 2002, Cancer research.

[20]  J. Rhim,et al.  Cadmium-induced neoplastic transformation of human prostate epithelial cells. , 2002, International journal of oncology.

[21]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Boulay,et al.  Transcription Regulation and Protein Subcellular Localization of the Truncated Basic Hair Keratin hHb1-ΔN in Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[23]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[25]  D. Bostwick,et al.  Human acid ceramidase is overexpressed but not mutated in prostate cancer , 2000, Genes, chromosomes & cancer.

[26]  C. Tso,et al.  Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. , 2000, Cancer journal.

[27]  Q. She,et al.  Growth factor‐like effects of placental alkaline phosphatase in human fetus and mouse embryo fibroblasts , 2000, FEBS letters.

[28]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[29]  P. Aarnisalo,et al.  Transcription Activating and Repressing Functions of the Androgen Receptor Are Differentially Influenced by Mutations in the Deoxyribonucleic Acid-Binding Domain. , 1999, Endocrinology.

[30]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[31]  C. Tokunaga,et al.  Mammalian Homologue of the Caenorhabditis elegans UNC-76 Protein Involved in Axonal Outgrowth Is a Protein Kinase C ζ–interacting Protein , 1999, The Journal of cell biology.

[32]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[33]  C. Conti,et al.  Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1 , 1998, Oncogene.

[34]  T. Meyer,et al.  The Rat Glucocorticoid Receptor Mutant K461A Differentiates between Two Different Mechanisms of Transrepression* , 1997, The Journal of Biological Chemistry.

[35]  J. Rhim,et al.  Loss of response to epidermal growth factor and retinoic acid accompanies the transformation of human prostatic epithelial cells to tumorigenicity with v-Ki-ras. , 1997, Carcinogenesis.

[36]  Tony Hunter,et al.  MNK1, a new MAP kinase‐activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates , 1997, The EMBO journal.

[37]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[39]  P. Weijerman,et al.  Characterization of adult human prostatic epithelial-cells immortalized by polybrene-induced DNA transfection with a plasmid containing an origin-defective sv40-genome. , 1994, International journal of oncology.

[40]  G. Mills,et al.  Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. , 1993, Cancer research.

[41]  M. Resnick,et al.  Xenografts of primary human prostatic carcinoma. , 1993, Journal of the National Cancer Institute.

[42]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Jenster,et al.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[44]  W. Fishman,et al.  Placental alkaline phosphatase as a tumor marker for seminoma. , 1982, Cancer research.

[45]  W. Fishman,et al.  Presence of the rare D-variant heat-stable, placental-type alkaline phosphatase in normal human testis. , 1980, Cancer research.

[46]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[47]  S. Loening,et al.  Carcinoplacental isoenzyme (regan) in carcinoma of the prostate , 1981, Cancer.